Brokers Offer Predictions for ANIP Q2 Earnings

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of ANI Pharmaceuticals in a research note issued on Thursday, July 10th. HC Wainwright analyst B. Folkes expects that the specialty pharmaceutical company will post earnings per share of $1.02 for the quarter. HC Wainwright currently has a "Buy" rating and a $84.00 target price on the stock. The consensus estimate for ANI Pharmaceuticals' current full-year earnings is $3.86 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals' Q3 2025 earnings at $1.13 EPS, Q4 2025 earnings at $1.40 EPS, FY2025 earnings at $4.94 EPS and FY2026 earnings at $5.64 EPS.

Several other equities research analysts also recently weighed in on the stock. Guggenheim reaffirmed a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Wall Street Zen cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Finally, Truist Financial lifted their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $78.88.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $64.96 on Monday. The company has a quick ratio of 1.98, a current ratio of 2.66 and a debt-to-equity ratio of 1.46. The company's 50 day moving average is $63.31 and its two-hundred day moving average is $62.37. The firm has a market cap of $1.41 billion, a PE ratio of -51.15 and a beta of 0.57. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.37 by $0.33. The firm had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The company's quarterly revenue was up 43.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.82 earnings per share.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ANIP. Hohimer Wealth Management LLC grew its holdings in ANI Pharmaceuticals by 5.2% during the first quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock worth $334,000 after acquiring an additional 247 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of ANI Pharmaceuticals by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock valued at $582,000 after buying an additional 364 shares in the last quarter. Natixis Advisors LLC boosted its position in shares of ANI Pharmaceuticals by 2.3% during the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after acquiring an additional 417 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock valued at $3,235,000 after purchasing an additional 423 shares during the last quarter. Finally, Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Institutional investors own 76.05% of the company's stock.

Insider Buying and Selling

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of the firm's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider owned 107,317 shares of the company's stock, valued at approximately $6,487,312.65. This trade represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the sale, the senior vice president owned 89,897 shares of the company's stock, valued at approximately $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,281 shares of company stock worth $319,270 over the last quarter. Company insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.